Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA.

Morimoto S, Tsuda M, Bunch H, Sasanuma H, Austin C, Takeda S.

Genes (Basel). 2019 Oct 30;10(11). pii: E868. doi: 10.3390/genes10110868. Review.

2.

The Deubiquitinating Enzyme Inhibitor PR-619 is a Potent DNA Topoisomerase II Poison.

Cowell IG, Ling EM, Swan RL, Brooks MLW, Austin CA.

Mol Pharmacol. 2019 Nov;96(5):562-572. doi: 10.1124/mol.119.117390. Epub 2019 Sep 12.

3.

Mutations in topoisomerase IIβ result in a B cell immunodeficiency.

Broderick L, Yost S, Li D, McGeough MD, Booshehri LM, Guaderrama M, Brydges SD, Kucharova K, Patel NC, Harr M, Hakonarson H, Zackai E, Cowell IG, Austin CA, Hügle B, Gebauer C, Zhang J, Xu X, Wang J, Croker BA, Frazer KA, Putnam CD, Hoffman HM.

Nat Commun. 2019 Aug 13;10(1):3644. doi: 10.1038/s41467-019-11570-6.

4.

Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.

Atwal M, Swan RL, Rowe C, Lee KC, Lee DC, Armstrong L, Cowell IG, Austin CA.

Mol Pharmacol. 2019 Oct;96(4):475-484. doi: 10.1124/mol.119.117259. Epub 2019 Aug 9.

PMID:
31399497
5.

A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents.

Blower TR, Bandak A, Lee ASY, Austin CA, Nitiss JL, Berger JM.

Nucleic Acids Res. 2019 Sep 5;47(15):8163-8179. doi: 10.1093/nar/gkz579.

6.

TOP2B: The First Thirty Years.

Austin CA, Lee KC, Swan RL, Khazeem MM, Manville CM, Cridland P, Treumann A, Porter A, Morris NJ, Cowell IG.

Int J Mol Sci. 2018 Sep 14;19(9). pii: E2765. doi: 10.3390/ijms19092765. Review.

7.

Effect of TDP2 on the Level of TOP2-DNA Complexes and SUMOylated TOP2-DNA Complexes.

Lee KC, Swan RL, Sondka Z, Padget K, Cowell IG, Austin CA.

Int J Mol Sci. 2018 Jul 14;19(7). pii: E2056. doi: 10.3390/ijms19072056.

8.

Visualization and Quantification of Topoisomerase-DNA Covalent Complexes Using the Trapped in Agarose Immunostaining (TARDIS) Assay.

Cowell IG, Austin CA.

Methods Mol Biol. 2018;1703:301-316. doi: 10.1007/978-1-4939-7459-7_21.

PMID:
29177750
9.

Topoisomerase II Chromatin Immunoprecipitation.

Smith KA, Cowell IG, Austin CA.

Methods Mol Biol. 2018;1703:183-189. doi: 10.1007/978-1-4939-7459-7_14.

PMID:
29177743
10.

Plant and Human MORC Proteins Have DNA-Modifying Activities Similar to Type II Topoisomerases, but Require One or More Additional Factors for Full Activity.

Manohar M, Choi HW, Manosalva P, Austin CA, Peters JE, Klessig DF.

Mol Plant Microbe Interact. 2017 Feb;30(2):87-100. doi: 10.1094/MPMI-10-16-0208-R. Epub 2017 Feb 3.

11.

Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.

Atwal M, Lishman EL, Austin CA, Cowell IG.

Mol Pharmacol. 2017 Jan;91(1):49-57. Epub 2016 Nov 10.

12.

Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.

Lee KC, Bramley RL, Cowell IG, Jackson GH, Austin CA.

Biochem Pharmacol. 2016 Mar 1;103:29-39. doi: 10.1016/j.bcp.2015.12.015. Epub 2016 Jan 12.

13.

Distinct expression patterns for type II topoisomerases IIA and IIB in the early foetal human telencephalon.

Harkin LF, Gerrelli D, Gold Diaz DC, Santos C, Alzu'bi A, Austin CA, Clowry GJ.

J Anat. 2016 Mar;228(3):452-63. doi: 10.1111/joa.12416. Epub 2015 Nov 27.

14.

Genome-wide ChIP-seq analysis of human TOP2B occupancy in MCF7 breast cancer epithelial cells.

Manville CM, Smith K, Sondka Z, Rance H, Cockell S, Cowell IG, Lee KC, Morris NJ, Padget K, Jackson GH, Austin CA.

Biol Open. 2015 Oct 12;4(11):1436-47. doi: 10.1242/bio.014308.

15.

Differential Targeting of Human Topoisomerase II Isoforms with Small Molecules.

Mariani A, Bartoli A, Atwal M, Lee KC, Austin CA, Rodriguez R.

J Med Chem. 2015 Jun 11;58(11):4851-6. doi: 10.1021/acs.jmedchem.5b00473. Epub 2015 May 20.

PMID:
25945730
16.

Brief reports: Controlling the survival of human pluripotent stem cells by small molecule-based targeting of topoisomerase II alpha.

Ben-David U, Cowell IG, Austin CA, Benvenisty N.

Stem Cells. 2015 Mar;33(3):1013-9. doi: 10.1002/stem.1888.

17.

Human Tra2 proteins jointly control a CHEK1 splicing switch among alternative and constitutive target exons.

Best A, James K, Dalgliesh C, Hong E, Kheirolahi-Kouhestani M, Curk T, Xu Y, Danilenko M, Hussain R, Keavney B, Wipat A, Klinck R, Cowell IG, Cheong Lee K, Austin CA, Venables JP, Chabot B, Santibanez Koref M, Tyson-Capper A, Elliott DJ.

Nat Commun. 2014 Sep 11;5:4760. doi: 10.1038/ncomms5760.

18.

The role of topoisomerase II beta on breakage and proximity of RUNX1 to partner alleles RUNX1T1 and EVI1.

Smith KA, Cowell IG, Zhang Y, Sondka Z, Austin CA.

Genes Chromosomes Cancer. 2014 Feb;53(2):117-28. doi: 10.1002/gcc.22124. Epub 2013 Nov 5.

19.

A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation.

Shapiro AB, Austin CA.

Anal Biochem. 2014 Mar 1;448:23-9. doi: 10.1016/j.ab.2013.11.029. Epub 2013 Dec 3.

20.

Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.

Bau JT, Kang Z, Austin CA, Kurz EU.

Mol Pharmacol. 2014 Feb;85(2):198-207. doi: 10.1124/mol.113.088963. Epub 2013 Nov 12.

PMID:
24220011

Supplemental Content

Loading ...
Support Center